Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are biosimilar insulin glargine analogs with identical amino acid sequence and similar pharmacological profiles.

ELEMENT 5, a Phase 3 study conducted in type 2 diabetes mellitus (T2DM) patients across multiple countries showed that efficacy and safety profiles of LY IGlar and IGlar were similar.

There are differences in the pathophysiology and clinical features of T2DM between Asians and their Western counterparts.

Efficacy and safety profiles of LY IGlar and IGlar, in combination with oral antihyperglycemic medications, were similar in India and East Asia subpopulations. These observations were consistent with the ELEMENT 5 total population.